Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. reports developments for a commercial pharmaceutical business that markets differentiated products primarily in oncology. Company updates focus on product sales, commercial execution, portfolio changes, and financial results for its single reportable segment, including activity tied to Rolvedon and other branded pharmaceutical assets.
Recent announcements also cover capital-structure and corporate governance matters, material agreements, shareholder-related processes, and completed portfolio transactions. Assertio has reported the sale of U.S. rights to several branded products, including INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP, while continuing to frame its commercial strategy around oncology-focused products.
Assertio Holdings, Inc. (Nasdaq: ASRT) will release its third-quarter 2022 financial results on November 8, 2022, after market close. A live webcast of the earnings call will follow at 4:30 p.m. ET. Investors can access the call via Assertio's investor relations website. The company focuses on specialty pharmaceuticals, utilizing a non-personal promotional model to enhance product differentiation. Assertio emphasizes growth opportunities through integrating new assets and business development initiatives.
Assertio Holdings has acquired an exclusive license for Sympazan (clobazam) oral film from Aquestive Therapeutics for $9.0 million upfront and an additional $6.0 million upon patent allowance, expected in 2023. This transaction aims to enhance Assertio's portfolio and extend patent coverage potentially to 2039. Sympazan, designed for LGS patients, is anticipated to contribute $4.0 - $4.5 million in adjusted EBITDA and $0.05 in adjusted EPS, aligning with Assertio's growth strategy to achieve $40 million in gross profit by 2024.
Assertio Holdings (Nasdaq: ASRT), a specialty pharmaceutical company, announced its participation in investor conferences during October 2022. Key events include the Windy City Roundup 2022 on October 13, 2022, at Swissotel, Chicago, and the LD Micro Main Event XV on October 25, 2022, at Luxe Sunset Boulevard Hotel, Los Angeles. Presentations will occur at 11:00 a.m. CT and 10:30 a.m. PT, respectively. Management will also host one-on-one meetings. For further details, interested parties should contact Investor Relations.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced that CEO Dan Peisert will participate in investor meetings on September 14, 2022, at the Lake Street Capital Markets Best Ideas Growth Conference (BIG6) in New York City. The event will include one-on-one meetings with management, providing an opportunity for investors to engage directly. Assertio specializes in differentiated pharmaceutical products across neurology, hospital, and pain/inflammation sectors and has grown through strategic business initiatives.
Assertio Holdings has successfully closed a $70 million offering of 6.50% convertible senior notes due 2027, including a full exercise of an option for an additional $10 million. The net proceeds of approximately $65.9 million will be used to repurchase existing debt and for general corporate purposes. The notes will accrue interest, payable semi-annually, and can be converted into cash or common stock at Assertio's discretion, with an initial conversion price of about $4.09 per share. The company prohibits incurring additional liens without securing the notes equally.
Assertio Holdings, Inc. (Nasdaq: ASRT) has priced a $60 million offering of 6.50% convertible senior notes due 2027, scheduled to settle on August 25, 2022. The company expects net proceeds of approximately $56.7 million, intended for repurchasing senior secured notes and general corporate purposes. The initial conversion rate is 244.2003 shares per $1,000 note, with a conversion price of $4.09, representing a 12.50% premium over the last stock price. The notes may be redeemed after September 8, 2025, under specific stock price conditions.
Assertio Holdings, Inc. (Nasdaq: ASRT) has announced its plan to offer $60 million in convertible senior notes due 2027, with the option for an additional $10 million. The notes, which will be senior and unsecured, will accrue semi-annual interest and can be converted into cash, shares, or a mix thereof. Proceeds are intended for repurchasing senior secured notes maturing in January 2024 and for general corporate purposes. The offering is a private placement, not registered under the Securities Act.
Assertio Holdings (ASRT) plans to disclose its second quarter 2022 financial results on August 8, 2022, prior to market opening. The management will host a live conference call at 11:30 a.m. ET to discuss the results. Interested parties can access the webcast via the company's investor relations website and should connect 10 minutes early to allow time for any necessary software downloads. A replay of the call will be available shortly after its conclusion.
Assertio specializes in differentiated pharmaceutical products, aiming to enhance its commercial portfolio through strategic opportunities.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced on July 12, 2022, that it granted new employees a total of 17,772 restricted stock units (RSUs) and 18,553 stock options effective July 1, 2022. This incentive aligns with NASDAQ Listing Rule 5635(c)(4) and is contingent on the employees' continued service. The options have an exercise price of $3.15 per share, matching the company's stock closing price on the grant date, with vesting scheduled over three years.
Assertio Holdings (NASDAQ: ASRT) announced its participation in the LD Micro Invitational XII Conference from June 7-9, 2022 at the Four Seasons Hotel in Westlake Village, CA. The Company will present on June 8, 2022, at 3:00 PM PT in Track 1, with opportunities for 1:1 meetings with investors throughout the day. Presentation information will be available on the event day at assertiotx.com. Investors can contact LD Micro or Matt Kreps from Darrow Associates for meeting inquiries.